Article

Dr. George Addresses Provider Issues Regarding Immunotherapies

Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, specifically discusses the immunotherapy agent, sipuleucel-T (Provenge) used in the treatment of prostate cancer.

Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, specifically discusses the immunotherapy agent, sipuleucel-T (Provenge) used in the treatment of prostate cancer. He says that when the drug first came on the market many administrative challenges existed. There were limited access and associated reimbursement issues due to the limited production capabilities. However, Dr George states that currently there are no issues with payer coverage with little to no delays when it comes to prescribing the agent.

This video was taken on June 1, 2013, at the ASCO Annual Meeting 2013 in Chicago, IL.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Carrie Kitko
Dr Ibrahim Aldoss
Dr Pankit Vachhani
Dr Ibrahim Aldoss
Dr Pankit Vachhani
Dr John Mascarenhas
CK Wang, MD, COTA
Dr Pankit Vachhani
Dr John Mascarenhas
Dr John Mascarenhas
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo